Generic name: selegiline hydrochloride
Dosage form: orally disintegrating tablet
The information at Drugs.com is not a substitute for medical advice. ALWAYS consult your doctor or pharmacist.
ZELAPAR® is intended for administration to patients with Parkinson's disease receiving levodopa/carbidopa therapy who demonstrate a deteriorating response to this treatment.
Treatment should be initiated with 1.25 mg given once a day for at least 6 weeks. After 6 weeks, the dose may be escalated to 2.5 mg given once a day if a desired benefit has not been achieved and the patient is tolerating ZELAPAR®. There is no evidence that doses greater than 2.5 mg a day confer any additional benefit, and they should ordinarily be avoided because of the potential increased risk of adverse events.
ZELAPAR® should be taken in the morning before breakfast and without liquid.
In the controlled trial of ZELAPAR® in which ZELAPAR® was shown to be effective compared to placebo, 17% of patients in the ZELAPAR® group and 19% of patients in the placebo treatment group had a reduction in their doses of levodopa/carbidopa because of perceived dopaminergic side effects. For those patients with a dose reduction, the average reduction was 24% for ZELAPAR® and 21% for placebo.
Patients should not attempt to push ZELAPAR® through the foil backing. Patients should PEEL BACK the backing of one or two blisters (as prescribed) with dry hands, and GENTLY remove the tablet(s). Patients should IMMEDIATELY place the ZELAPAR® tablet(s) on top of the tongue where it will disintegrate in seconds. Patients should avoid ingesting food or liquids for 5 minutes before and after taking ZELAPAR®.
More about Zelapar (selegiline)
- Zelapar orally disintegrating tablets
- Zelapar (Advanced Reading)
- Zelapar Oral (Advanced Reading)